EORTC risk tables: Predicting recurrence and progression in stage Ta T1 bladder cancer patients. (5yr Progression)
In order to predict, separately, the short- and long-term risks of disease recurrence and progression in individual patients, the EORTC Genito-Urinary Cancer Group has developed a scoring system and risk tables.

The scoring system is based on the six most significant clinical and pathological factors. 

The EORTC tables were developed to provide an easy calculation of the estimated recurrence, and progression probabilities of bladder cancer over 1- and 5-years. Current model calculates the 5-year probability of disease progression. 
Research authors: Richard J. Sylvester, Adrian P.M. van der Meijden, Willem Oosterlinck, J. Alfred Witjes, Christian Bouffioux, Louis Denis, Donald W.W. Newling, Karlheinz Kurth
Details Formula Study characteristics Files & References
★★★★
Model author
Model ID
1024
Version
1.3
Revision date
2017-11-09
Specialty
MeSH terms
  • Bladder Cancer
  • Recurrence
  • Disease Progression
  • Urology
  • Carcinoma in Situ
  • Model type
    Custom model (Conditional)
    Status
    public
    Rating
    Share
    Condition Formula

    Additional information

    A combined analysis was carried out of individual patient data from 2596 superficial bladder cancer patients included in seven European Organization for Research and Treatment of Cancer trials.

    Study Population

    Total population size: 2596

    Categorical characteristics

    Name Subset / Group Nr. of patients
    Intravesical treatment No 561
    Yes 2035
    Age (years) ≤60 859
    61-70 890
    71-80 690
    >80 118
    Unknown 39
    Gender Male 2044
    Female 515
    Unknown 37
    Prior treatment No 2358
    Yes 187
    Unknown 51
    Prior recurrence rate Primary 1405
    Recurrent, ≤1 rec/yr 505
    Recurrent, >1 rec/yr 645
    Unknown 41
    No. of tumors 1 1465
    2-7 836
    ≥8 255
    Unknown 40
    T category Ta 1451
    T1 1108
    Unknown 37
    Carcinoma in situ No 2440
    Yes 113
    Unknown 43
    Grade G1 1121
    G2 1139
    G3 271
    Unknown 65
    T1 G3 No 2361
    Yes, no CIS 172
    Yes, with CIS 22
    Unknown 41
    Recurrence at 3 months No 2070
    Yes 313
    Unknown 213
    Recurrence No 1356
    Yes 1240
    Progression No 2317
    Yes 279
    Survival Alive 1743
    Dead 853
    Cause of death Alive 1743
    Malignant disease 262
    Other 461
    Missing 130

    Estimated 5 year progression probability:
    ...
    %

    {{ resultSubheader }}

    {{ model.survival.PITTitle }}

    {{ model.survival.YNETitle }}

    Result
    Note
    Notes are only visible in the result download and will not be saved by Evidencio

    Estimated 5 year progression probability: %

    {{ resultSubheader }}
    {{ chart.title }}

    Outcome stratification

    Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

    Conditional information

    Result interpretation

    With these probabilities, the urologist can discuss the different options with the patient to determine the most appropriate treatment and frequency of follow-up.

    It should be noted that external validations of the EORTC tables were not always very good. The external validation in non-muscle-invasive urothelial bladder carcinoma patients by Xylinas et al. showed poor discrimination with C-statistics between 0.597 - 0.662 for the EORTC risk tables. 

    Still, the tables are recommended in the EAU guidelines on Non-muscle-invasive Bladder Cancer

    {{ file.classification }}

    Calculations alone should never dictate patient care, and are no substitute for professional judgement. See our full disclaimer.

    Comments
    Rating
    Comment
    Please enter a comment of rating
    Comments are visible to anyone

    Model feedback

    No feedback yet 1 Comment {{ model.comments.length }} Comments
    Not rated | On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
    logo

    Please sign in to enable Evidencio print features

    In order to use the Evidencio print features, you need to be logged in.
    If you don't have an Evidencio Community Account you can create your free personal account at:

    https://www.evidencio.com/registration

    Printed results - Examples {{ new Date().toLocaleString() }}


    Evidencio Community Account Benefits


    With an Evidencio Community account you can:

    • Create and publish your own prediction models.
    • Share your prediction models with your colleagues, research group, organization or the world.
    • Review and provide feedback on models that have been shared with you.
    • Validate your models and validate models from other users.
    • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
    • Use and save prediction models and their data.
    • Use patient specific protocols and guidelines based on sequential models and decision trees.
    • Stay up-to-date with new models in your field as they are published.
    • Create your own lists of favorite models and topics.
    A personal Evidencio account is free, with no strings attached! Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.

    Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.